Sugi Predict

Sugi Predict / Compounds / SCHEMBL764948

SCHEMBL764948

SCHEMBL764948

CC(C)Cc1ccc(/C=C/C(=O)O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.61
▸ MAPK1 P28482 1/20 0.61
▸ SMN1; SMN2 Q16637 4/20 0.60
▸ NPC1 O15118 3/20 0.60
▸ RAB9A P51151 3/20 0.60
▸ ALDH1A1 P00352 2/20 0.60
▸ MEN1 O00255 1/20 0.60
▸ POLB P06746 1/20 0.60
▸ KMT2A Q03164 1/20 0.60
▸ L3MBTL1 Q9Y468 1/20 0.60
▸ ESR1 P03372 3/20 0.53
▸ HCAR2 Q8TDS4 2/20 0.53
▸ CA12 O43570 1/20 0.53
▸ AKR1B10 O60218 1/20 0.53
▸ CA1 P00915 1/20 0.53
▸ CA2 P00918 1/20 0.53
▸ CA3 P07451 1/20 0.53
▸ PKM P14618 1/20 0.53
▸ TYR P14679 1/20 0.53
▸ AKR1B1 P15121 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7825300 1.00 KDM4E (0.61) KDM4EMAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL25146563 0.95 SMN1; SMN2 (0.56) KDM4EMAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL25146586 0.95 SMN1; SMN2 (0.56) KDM4EMAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL10410677 0.86 KDM4E (0.57) KDM4EMAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL25524702 0.86 NPC1 (0.60) KDM4EMAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL17288968 0.85 KDM4E (0.65) KDM4EMAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL10409219 0.85 KDM4E (0.56) KDM4EMAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL13103431 0.85 KDM4E (0.56) KDM4EMAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL4355522 0.84 NPC1 (0.67) KDM4EMAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL25516475 0.84 NPC1 (0.62) KDM4EMAPK1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117380269-B Oil-soluble organic molybdenum catalyst and preparation method and application thereof 北京高新利华科技股份有限公司 2024-04-05 — — CN disclosed
CN-117380269-A Oil-soluble organic molybdenum catalyst and preparation method and application thereof 北京高新利华科技股份有限公司 2024-01-12 — — CN disclosed
US-10544179-B2 Organic compounds GIVAUDAN S.A. (CH) 2020-01-28 — — US disclosed
EP-3097067-B1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2019-07-17 — — EP disclosed
US-10196414-B2 Organic compounds GIVAUDAN S.A. (CH) 2019-02-05 — — US disclosed
US-20180066003-A1 ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2018-03-08 — — US disclosed
WO-2017192991-A1 SELECTIVE ESTROGEN RECEPTOR DOWN-REGULATORS (SERDS) XAVIER UNIVERSITY OF LOUISIANA (US) 2017-11-09 — — WO disclosed
EP-3097067-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS Givaudan S.A. (CH) 2016-11-30 — — EP disclosed
US-20160326199-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN S.A. (CH) 2016-11-10 — — US disclosed
US-9102599-B2 N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases BRISTOL-MYERS SQUIBB COMPANY (US) 2015-08-11 — — US disclosed
WO-2009009716-A1 POLYMERIC DRUG DELIVERY SYSTEMS CONTAINING AN AROMATIC ALLYLIC ACID ENZON PHARMACEUTICALS, INC. (US) 2009-01-15 — — WO disclosed
US-20070161685-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-07-12 — — US disclosed
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 — — US disclosed
US-20070135467-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 — — US disclosed
US-20070135467-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 — — US disclosed
WO-2007062314-A2 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-31 — — WO disclosed
WO-2007062308-A2 HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-31 — — WO disclosed
WO-2007062342-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-31 — — WO disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 — — EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161685-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 KDM4E 1618/4885MAPK1 3848/4885SMN1; SMN2 4707/4885
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 KDM4E 1618/4885MAPK1 3848/4885SMN1; SMN2 4707/4885
US-20070135467-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 KDM4E 1618/4885MAPK1 3848/4885SMN1; SMN2 4707/4885
US-20160326199-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS PSPH, AS3MT, TST KDM4E 3955/4885MAPK1 4411/4885SMN1; SMN2 2052/4885
US-10196414-B2 Organic compounds SOST, TST, MPST KDM4E 4003/4885MAPK1 4451/4885SMN1; SMN2 3789/4885
US-20180066003-A1 ORGANIC COMPOUNDS SOST, TST, MPST KDM4E 4003/4885MAPK1 4451/4885SMN1; SMN2 3789/4885
US-10544179-B2 Organic compounds SOST, TST, MPST KDM4E 4003/4885MAPK1 4451/4885SMN1; SMN2 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.